Soligenix Inc. (SNGX) Recent Headlines
SNGX: Innate Defense Regulators Offer New Approach to Treating Infections
Soligenix, Inc. (SNGX) recently published a review of the potential clinical applications for innate defense regulators (IDRs), including the company’s lead IDR asset SGX942. IDRs modulate the innate immune response, which is composed of both physical barriers (e.g., skin, mucosal surfaces, etc.) as well as specialized myeloid and lymphoid sensor and effector cells (Gasteiger et al., 2017). IDRs exert their effects through binding of p62 (sequestosome-1), which is involved in a number of different innate immune signaling networks (Yu et al., 2009).
Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®
PRINCETON, N.J., Feb. 11, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the allowance of a new United States (US) patent protecting its ricin toxin vaccine, RiVax®. The patent, titled "Multivalent Stable Vaccine Composition and Methods of making same", supports combination vaccines protecting against ricin intoxication as well as other toxins, such as those associated with anthrax. RiVax® is the Company's vaccine candidate for the prevention of death following exposure to a lethal dose of ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. The RiVax® antigen has demonstrated safety in two Phase 1 clinical studies.
PRINCETON, N.J., Feb. 7, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of a scientific article demonstrating the successful thermostabilization of an Ebola subunit vaccine candidate. The article titled, "Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide", is published in the European Journal of Pharmaceutics and Biopharmaceutics online and is available here. As previously announced, Soligenix has been collaborating with the University of Hawai'i at Mānoa (UH Mānoa) and Hawaii Biotechnology, Inc. (HBI) on the development of a multivalent subunit vaccine for Ebola and Marburg infections.
Soligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator Analogs
PRINCETON, N.J., Jan. 23, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted the patent entitled "Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity." The newly issued patent claims composition of matter of innate defense regulator (IDR) analogs, expanding patent protection around the Company's lead IDR, dusquetide. Similar claims have been previously allowed in the United States (US) and are being pursued in other worldwide jurisdictions.
The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 10) Homology Medicines Inc (NASDAQ: FIXX ) OvaScience Inc ...
PRINCETON, N.J., Dec. 11, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's (NJEDA) New Jersey Technology Business Tax Certificate Transfer program. As a result, the Company anticipates being able to transfer this credit and receive approximately $611,000 in net proceeds by year end. This competitive program enables approved technology and biotechnology businesses to sell their unused Net Operating Loss (NOL) Carryovers and unused Research and Development (R&D) Tax Credits to unaffiliated, profitable corporate taxpayers in the state of New Jersey.
PRINCETON, N.J., Dec. 5, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of a review article discussing the therapeutic applications of its innate immune modulator technology, including dusquetide (the active ingredient in SGX942), its lead clinical Innate Defense Regulator (IDR). The article entitled, "Targeting Innate Immunity to Treat Disease: Potential Therapeutic Applications", is published in the journal Drug Target Review online and is available here. Innate immune modulation as a therapeutic intervention reflects our enhanced understanding of an ancient aspect of the immune system. With our increasingly sophisticated exploration of innate immunity, it has become possible to manipulate this system in a beneficial manner, potentially benefiting a wide range of patient populations, including oncology, oncology supportive care, infectious disease and acute and chronic inflammatory conditions. These applications have been made possible by recent studies identifying the intricacies of the signaling pathways, and the ability to differentially impact these pathways. Dusquetide is one of the first therapeutic approaches in this field, and is initially being developed in the context of oncology supportive care. Preclinical data with dusquetide has demonstrated a wide range of potential application, including in gastrointestinal inflammation, infectious disease and oncology, discussed in the presentation here. This brief review explores some of these concepts and proposes that innate immune modulation may become as important as other adaptive immune approaches (e.g., checkpoint inhibitors, CAR-T therapies) in the future.
SNGX: Two Phase 3 Data Readouts Over Next 12-15 Months…
Revenues were comprised of non-dilutive government grants and contracts in support of RiVax®, SGX301, and SGX942 as well as a subaward from the Ebola collaboration with the University of Hawaii. The increase was mainly due to increased costs associated with the ongoing Phase 3 clinical trials. As of September 30, 2018, Soligenix had cash and cash equivalents of $11.7 million, due in part to a registered direct offering in July 2018 that raised net proceeds of $8.4 million.
PRINCETON, N.J., Nov. 12, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing development of the vaccine under the Food and Drug Administration (FDA) Animal Rule. The presentation will be given at the upcoming Fourth International Conference on Vaccines Research & Development on November 13-15, 2018 to be held at the Radisson Hotel Baltimore Downtown-Inner Harbor, MD.
Soligenix Announces Recent Accomplishments And Third Quarter 2018 Financial Results
PRINCETON, N.J., Nov. 9, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the third quarter ended September 30, 2018. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "Our primary focus remains the quality execution of our two pivotal Phase 3 clinical programs. Following the positive recommendation recently received from the independent Data Monitoring Committee (DMC), we continue to enroll patients in our double-blind, placebo-controlled Phase 3 study for the treatment of cutaneous T-cell lymphoma (CTCL) with SGX301 (synthetic hypericin).
Soligenix Inc. (SNGX) Research Links
Soligenix Inc. (NYSE: SNGX) Stock Message Board
| 3 | 18% .7M C1.97 steady climb with a couple of pull | znewcar1 | 09/27/2018 4:24:52 PM |
| 2 | $SNGX called bottom play and a 100% strong sell | PoemStone | 07/17/2017 7:37:18 PM |
| 1 | #SNGX looking for bottom $ | PoemStone | 06/07/2017 5:24:44 PM |
